

Haematologica
HAEMATOL/2016/143677
Version 3

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

Haifa Kathrin Al-Ali, Martin Griesshammer, Philipp le Coutre, Cornelius F. Waller, Anna Marina Liberati, Philippe Schafhausen, Renato Tavares, Pilar Giraldo, Lynda Foltz, Pia Raanani, Vikas Gupta, Bayane Tannir, Julian Perez Ronco, Jagannath Ghosh, Bruno Martino, and Alessandro M. Vannucchi

Disclosures: H.K.A.-A. received research funding, travel grants, and honoraria and attended advisor boards for Novartis and Celgene. M.G., P.L., C.F.W., A.M.L., P.G., P.R., and B.M. have no relevant financial relationships to disclose. P.S. owns stock in Incyte Corp. R.T. reports grants and personal fees from Novartis during the conduct of the study and grants and personal fees from Bristol-Meyers Squibb and personal fees from Janssen outside of the submitted work. L.F. reports grants and non-financial support from Novartis during the conduct of the study; grants, personal fees, and non-financial support from Novartis, grants from Gilead, and grants from Incyte Corp outside of the submitted work. V.G. reports grants, personal fees, and other from Novartis and grants from Incyte during the conduct of the study. B.T. and J.P.R. are employees of and own stock in Novartis Pharma AG. J.G. is an employee of Novartis Pharmaceuticals Corporation. A.M.V. reports grants and personal fees from Novartis during the conduct of the study.

Contributions: H.K.A.-A., M.G., P.L., C.F.W., A.M.L., P.S., R.T., P.G., L.F., P.R., V.G., B.M., and A.M.V. contributed to study design, data collection, and data interpretation and performed the research. B.T., J.P.R., and J.G. contributed to study design and data interpretation. J.G. performed statistical analyses. All authors were involved with drafting the manuscript and approved the final version.